🇪🇺 Metformin plus vildagliptin in European Union

EMA authorised Metformin plus vildagliptin on 14 November 2007

Marketing authorisation

EMA — authorised 14 November 2007

  • Application: EMEA/H/C/000807
  • Marketing authorisation holder: Novartis Europharm Limited
  • Local brand name: Eucreas
  • Indication: Eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
  • Status: approved

Read official source →

Other Diabetes approved in European Union

Frequently asked questions

Is Metformin plus vildagliptin approved in European Union?

Yes. EMA authorised it on 14 November 2007.

Who is the marketing authorisation holder for Metformin plus vildagliptin in European Union?

Novartis Europharm Limited holds the EU marketing authorisation.